Cargando…
Efficacy and tolerability of EPs 7630 in patients (aged 6–18 years old) with acute bronchitis
AIM: For EPs-7630, a herbal drug preparation from Pelargonium sidoides roots, therapeutic effects in respiratory tract infections outside the strict indication for antibiotics have already been demonstrated in adults. Now, a dose-finding study for EPs-7630 was performed in children and adolescents....
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855831/ https://www.ncbi.nlm.nih.gov/pubmed/20070280 http://dx.doi.org/10.1111/j.1651-2227.2009.01656.x |
_version_ | 1782180214948757504 |
---|---|
author | Kamin, W Maydannik, VG Malek, FA Kieser, M |
author_facet | Kamin, W Maydannik, VG Malek, FA Kieser, M |
author_sort | Kamin, W |
collection | PubMed |
description | AIM: For EPs-7630, a herbal drug preparation from Pelargonium sidoides roots, therapeutic effects in respiratory tract infections outside the strict indication for antibiotics have already been demonstrated in adults. Now, a dose-finding study for EPs-7630 was performed in children and adolescents. METHODS: A total of 400 patients (aged 6–18 years) were randomized to receive either 30 mg, 60 mg or 90 mg EPs-7630 or placebo daily. Primary outcome criterion was the change in the Bronchitis Severity Score (BSS) from day 0 to day 7. RESULTS: After 7 days of treatment, the change in the BSS total score was significantly better in the 60 mg and 90 mg groups compared with placebo that of the without relevant differences between these two dosages. Especially ‘coughing’, ‘sputum’ and ‘rales at auscultation’ improved under EPs-7630. Onset of effect was faster, time of bed rest shorter and treatment outcome and satisfaction with treatment were rated better. Tolerability was comparable with placebo in all treatment groups. CONCLUSION: EPs-7630 is effective in acute bronchitis outside the strict indication for antibiotics in 6–18 years old patients, with a dose of 60 mg or 90 mg daily offering the best benefit/risk ratio. EPs-7630 significantly reduces the severity of symptoms, leads to a more favourable course of the disease and a faster recovery from acute bronchitis compared with the placebo, and is well tolerated. |
format | Text |
id | pubmed-2855831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-28558312010-04-26 Efficacy and tolerability of EPs 7630 in patients (aged 6–18 years old) with acute bronchitis Kamin, W Maydannik, VG Malek, FA Kieser, M Acta Paediatr Regular Articles AIM: For EPs-7630, a herbal drug preparation from Pelargonium sidoides roots, therapeutic effects in respiratory tract infections outside the strict indication for antibiotics have already been demonstrated in adults. Now, a dose-finding study for EPs-7630 was performed in children and adolescents. METHODS: A total of 400 patients (aged 6–18 years) were randomized to receive either 30 mg, 60 mg or 90 mg EPs-7630 or placebo daily. Primary outcome criterion was the change in the Bronchitis Severity Score (BSS) from day 0 to day 7. RESULTS: After 7 days of treatment, the change in the BSS total score was significantly better in the 60 mg and 90 mg groups compared with placebo that of the without relevant differences between these two dosages. Especially ‘coughing’, ‘sputum’ and ‘rales at auscultation’ improved under EPs-7630. Onset of effect was faster, time of bed rest shorter and treatment outcome and satisfaction with treatment were rated better. Tolerability was comparable with placebo in all treatment groups. CONCLUSION: EPs-7630 is effective in acute bronchitis outside the strict indication for antibiotics in 6–18 years old patients, with a dose of 60 mg or 90 mg daily offering the best benefit/risk ratio. EPs-7630 significantly reduces the severity of symptoms, leads to a more favourable course of the disease and a faster recovery from acute bronchitis compared with the placebo, and is well tolerated. Blackwell Publishing Ltd 2010-04 /pmc/articles/PMC2855831/ /pubmed/20070280 http://dx.doi.org/10.1111/j.1651-2227.2009.01656.x Text en Journal Compilation © 2010 Foundation Acta Pædiatrica http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Regular Articles Kamin, W Maydannik, VG Malek, FA Kieser, M Efficacy and tolerability of EPs 7630 in patients (aged 6–18 years old) with acute bronchitis |
title | Efficacy and tolerability of EPs 7630 in patients (aged 6–18 years old) with acute bronchitis |
title_full | Efficacy and tolerability of EPs 7630 in patients (aged 6–18 years old) with acute bronchitis |
title_fullStr | Efficacy and tolerability of EPs 7630 in patients (aged 6–18 years old) with acute bronchitis |
title_full_unstemmed | Efficacy and tolerability of EPs 7630 in patients (aged 6–18 years old) with acute bronchitis |
title_short | Efficacy and tolerability of EPs 7630 in patients (aged 6–18 years old) with acute bronchitis |
title_sort | efficacy and tolerability of eps 7630 in patients (aged 6–18 years old) with acute bronchitis |
topic | Regular Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855831/ https://www.ncbi.nlm.nih.gov/pubmed/20070280 http://dx.doi.org/10.1111/j.1651-2227.2009.01656.x |
work_keys_str_mv | AT kaminw efficacyandtolerabilityofeps7630inpatientsaged618yearsoldwithacutebronchitis AT maydannikvg efficacyandtolerabilityofeps7630inpatientsaged618yearsoldwithacutebronchitis AT malekfa efficacyandtolerabilityofeps7630inpatientsaged618yearsoldwithacutebronchitis AT kieserm efficacyandtolerabilityofeps7630inpatientsaged618yearsoldwithacutebronchitis |